

# Philip Barter

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10486814/publications.pdf>

Version: 2024-02-01

49  
papers

15,123  
citations

101543

36  
h-index

197818

49  
g-index

51  
all docs

51  
docs citations

51  
times ranked

18003  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence of plasma lipid disorders with an emphasis on LDL cholesterol in selected countries in the Asia-Pacific region. <i>Lipids in Health and Disease</i> , 2021, 20, 33.	3.0	20
2	Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity. <i>Nature Reviews Endocrinology</i> , 2020, 16, 177-189.	9.6	790
3	Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 715-725.	11.4	687
4	HDL cholesterol and ASCVD risk stratification: A debate. <i>Atherosclerosis</i> , 2019, 283, 7-12.	0.8	43
5	Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial. <i>Circulation</i> , 2018, 138, 770-781.	1.6	126
6	Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk. <i>Journal of Clinical Lipidology</i> , 2018, 12, 130-136.	1.5	44
7	Expert opinion on the applicability of dyslipidemia guidelines in Asia and the Middle East. <i>International Journal of General Medicine</i> , 2018, Volume 11, 313-322.	1.8	33
8	Effects of the BET-inhibitor, RVX-208 on the HDL lipidome and glucose metabolism in individuals with prediabetes: A randomized controlled trial. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 904-914.	3.4	37
9	Dyslipidaemia in the Middle East: Current status and a call for action. <i>Atherosclerosis</i> , 2016, 252, 182-187.	0.8	37
10	Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East. <i>International Journal of Cardiology</i> , 2016, 225, 268-283.	1.7	17
11	Dysfunctional HDL and atherosclerotic cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2016, 13, 48-60.	13.7	547
12	Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Tj ETQq0 0 0 rgBT /Overlock 10 Tf 2015, 9, 65-71.	1.5	24
13	Prediction of Cardiovascular Events in Statin-Treated Stable Coronary Patients of the Treating to New Targets Randomized Controlled Trial by Lipid and Non-Lipid Biomarkers. <i>PLoS ONE</i> , 2014, 9, e114519.	2.5	38
14	Antioxidant Effects of Statins in the Management of Cardiometabolic Disorders. <i>Journal of Atherosclerosis and Thrombosis</i> , 2014, 21, 997-1010.	2.0	39
15	Lipids, Safety Parameters, and Drug Concentrations After an Additional 2 Years of Treatment With Anacetrapib in the DEFINE Study. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2014, 19, 543-549.	2.0	41
16	Evaluation of Lipids, Drug Concentration, and Safety Parameters Following Cessation of Treatment With the Cholesteryl Ester Transfer Protein Inhibitor Anacetrapib in Patients With or at High Risk for Coronary Heart Disease. <i>American Journal of Cardiology</i> , 2014, 113, 76-83.	1.6	78
17	Residual macrovascular risk in 2013: what have we learned?. <i>Cardiovascular Diabetology</i> , 2014, 13, 26.	6.8	149
18	An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia-Full report. <i>Journal of Clinical Lipidology</i> , 2014, 8, 29-60.	1.5	289

#	ARTICLE	IF	CITATIONS
19	Impact of High-Dose Atorvastatin Therapy and Clinical Risk Factors on Incident Aortic Valve Stenosis in Patients With Cardiovascular Disease (from TNT, IDEAL, and SPARCL). American Journal of Cardiology, 2014, 113, 1378-1382.	1.6	27
20	Translation of High-Density Lipoprotein Function Into Clinical Practice. Circulation, 2013, 128, 1256-1267.	1.6	197
21	Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib. Journal of Lipid Research, 2013, 54, 467-472.	4.2	52
22	The 719Arg Variant of KIF6 and Cardiovascular Outcomes in Statin-Treated, Stable Coronary Patients of the Treating to New Targets and Incremental Decrease in End Points Through Aggressive Lipid-Lowering Prospective Studies. Circulation: Cardiovascular Genetics, 2012, 5, 51-57.	5.1	21
23	A Genome-Wide Association Search for Type 2 Diabetes Genes in African Americans. PLoS ONE, 2012, 7, e29202.	2.5	197
24	The emerging role of HDL in glucose metabolism. Nature Reviews Endocrinology, 2012, 8, 237-245.	9.6	214
25	Diabetic dyslipidaemia in Asian populations in the Western Pacific Region: What we know and don't know. Diabetes Research and Clinical Practice, 2011, 94, 1-13.	2.8	17
26	Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: where are we now?. Trends in Pharmacological Sciences, 2011, 32, 694-699.	8.7	24
27	Predictors of New-Onset Diabetes in Patients Treated With Atorvastatin. Journal of the American College of Cardiology, 2011, 57, 1535-1545.	2.8	305
28	Introduction. Atherosclerosis Supplements, 2011, 12, 265-266.	1.2	8
29	HDL-C: Role as a risk modifier. Atherosclerosis Supplements, 2011, 12, 267-270.	1.2	87
30	Impact of statins on progression of atherosclerosis: rationale and design of SATURN (Study of) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 307. Current Medical Research and Opinion, 2011, 27, 1119-1129.	1.9	43
31	Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy. JAMA - Journal of the American Medical Association, 2011, 305, 2556.	7.4	1,197
32	Lipid management after a coronary event. , 2011, , 328-337.		0
33	Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease. New England Journal of Medicine, 2010, 363, 2406-2415.	27.0	697
34	New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nature Genetics, 2010, 42, 105-116.	21.4	1,982
35	Prospective studies on the relationship between high-density lipoprotein cholesterol and cardiovascular risk: a systematic review. European Journal of Cardiovascular Prevention and Rehabilitation, 2009, 16, 404-423.	2.8	48
36	Lessons Learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) Trial. American Journal of Cardiology, 2009, 104, 10E-15E.	1.6	86

#	ARTICLE	IF	CITATIONS
37	Design of the DEFINE trial: Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib. American Heart Journal, 2009, 158, 513-519.e3.	2.7	85
38	Evaluating the Incremental Benefits of Raising High-Density Lipoprotein Cholesterol Levels During Lipid Therapy After Adjustment for the Reductions in Other Blood Lipid Levels. Archives of Internal Medicine, 2009, 169, 1775-80.	3.8	61
39	Evolving Targets of Therapy. , 2009, , 387-395.		0
40	Intensive Lipid-Lowering With Atorvastatin for Secondary Prevention in Patients After Coronary Artery Bypass Surgery. Journal of the American College of Cardiology, 2008, 51, 1938-1943.	2.8	87
41	Lipids, Apolipoproteins, and Their Ratios in Relation to Cardiovascular Events With Statin Treatment. Circulation, 2008, 117, 3002-3009.	1.6	405
42	HDL Cholesterol, Very Low Levels of LDL Cholesterol, and Cardiovascular Events. New England Journal of Medicine, 2007, 357, 1301-1310.	27.0	1,390
43	International Day for the Evaluation of Abdominal Obesity (IDEA). Circulation, 2007, 116, 1942-1951.	1.6	599
44	Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet, The, 2006, 368, 919-928.	13.7	369
45	Effects of High-Dose Atorvastatin on Cerebrovascular Events in Patients With Stable Coronary Disease in the TNT (Treating to New Targets) Study. Journal of the American College of Cardiology, 2006, 48, 1793-1799.	2.8	63
46	Are we lowering LDL cholesterol sufficiently?. Nature Clinical Practice Cardiovascular Medicine, 2006, 3, 290-291.	3.3	7
47	Effect of Lowering LDL Cholesterol Substantially Below Currently Recommended Levels in Patients With Coronary Heart Disease and Diabetes: The Treating to New Targets (TNT) study. Diabetes Care, 2006, 29, 1220-1226.	8.6	493
48	National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand. Heart Lung and Circulation, 2005, 14, 275-291.	0.4	115
49	Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease. New England Journal of Medicine, 2005, 352, 1425-1435.	27.0	3,152